hrcak mascot   Srce   HID

Veterinary Archives, Vol.82 No.2 March 2012.

Original scientific paper

Attenuation of interleukin- 1β secretion in mice by post-inflammatory treatment with azithromycin and clarithromycin.

Vanesa Ivetić Tkalčević ; GSK Research Centre Zagreb Ltd., Zagreb, Croatia
Vesna Eraković Haber ; GSK Research Centre Zagreb Ltd., Zagreb, Croatia

Fulltext: english, pdf (178 KB) pages 201-209 downloads: 150* cite
APA
Ivetić Tkalčević, V., Eraković Haber, V. (2012). Attenuation of interleukin- 1β secretion in mice by post-inflammatory treatment with azithromycin and clarithromycin.. Veterinarski arhiv, 82(2), 201-209. Retrieved from http://hrcak.srce.hr/78273

Abstracts
The literature indicates that, in addition to anti-bacterial effects, certain macrolide antibiotics, such as azithromycin and clarithromycin, also exert anti-inflammatory and immunomodulatory activity, by accumulating in inflammatory cells and inhibiting the secretion of pro-inflammatory cytokines. Previous reports have shown that pre-treatment with these macrolides attenuates induced immediate skin inflammatory reactions in mice. However, the anti inflammatory activity of the post-inflammatory induction of macrolide antibiotics in this experimental model has not been investigated. The aim of this study was to explore whether the anti-inflammatory activity of azithromycin and clarithromycin, applied transdermally, 30 min after a phorbol 12-myristate 13- acetate (PMA)-induced immediate skin inflammation in mice, could attenuate a Th1 inflammatory reaction. The capacity of azithromycin and clarithromycin (500 μg/ear) to exert anti-inflammatory effects, similar to those of dexamethasone (50 μg/ear), was confirmed by the inhibition by all three agents of ear swelling and interleukin- 1β concentration in the ear tissue of PMA-treated mice, supporting this clinically relevant treatment mode.

Keywords
anti-inflammatory activity; IL-1β; macrolide antibiotic; mouse; skin inflammatio

Hrčak ID: 78273

URI
http://hrcak.srce.hr/78273

[croatian]

Visits: 296 *